New milestone reached for neuroprotective drug developed in WA
A neuroprotective drug developed in Western Australia has been granted Rare Pediatric Disease Designation (RPDD) by the U.S. Food and...
Continue reading
This website may not work correctly in Internet Explorer. We recommend switching to a more secure modern web browser such as Microsoft Edge which is already installed on your computer.
Our Stroke Research Group is led by Clinical Professor Neville Knuckey and Adjunct Professor Bruno Meloni. The group’s core focus is to develop neuroprotective treatments to minimise brain damage after a stroke, and other neurological disorders causing brain injury.
After discovering peptides rich in the amino acid arginine are highly neuroprotective and can limit brain damage after a stroke, the team have been working to develop a lead peptide known as ARG-007 as a potential therapy. The therapy would allow us to accomplish our current focus and extend the therapeutic time window for medical interventions to break up the blood clot or to remove the clot in the brain’s blood vessel which caused the stroke, ultimately preserving brain tissue and improving patient outcome. To progress ARG-007 to the clinic, the UWA and Perron Institute ASX listed spin-out company Argenica Therapeutics was established in 2021. In addition, ongoing research is exploring the potential application of ARG-007 as a neuroprotective treatment for other neurological conditions such as neonatal asphyxia, traumatic brain injury and Parkinson’s disease.
The Stroke Clinic provides a comprehensive and ongoing service for people who have suffered from a stroke.
Keep informed with our latest updates.
Stay up to date with our latest news and announcements.